Accuray Incorporated (NASDAQ:ARAY) Shares Sold by Kovack Advisors Inc.

Kovack Advisors Inc. lessened its holdings in Accuray Incorporated (NASDAQ:ARAY) by 2.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,104,950 shares of the medical equipment provider’s stock after selling 25,400 shares during the quarter. Kovack Advisors Inc.’s holdings in Accuray were worth $3,127,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Dynamic Advisor Solutions LLC boosted its position in Accuray by 39.8% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 32,155 shares of the medical equipment provider’s stock worth $89,000 after purchasing an additional 9,155 shares in the last quarter. Barclays PLC lifted its holdings in Accuray by 25.8% in the 3rd quarter. Barclays PLC now owns 46,169 shares of the medical equipment provider’s stock valued at $126,000 after purchasing an additional 9,476 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Accuray by 28.0% in the 4th quarter. SG Americas Securities LLC now owns 45,862 shares of the medical equipment provider’s stock valued at $130,000 after purchasing an additional 10,046 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in Accuray in the 3rd quarter valued at $35,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Accuray in the 3rd quarter worth $42,000. Institutional investors and hedge funds own 64.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on ARAY shares. TheStreet downgraded Accuray from a “c-” rating to a “d+” rating in a research note on Wednesday, February 14th. Roth Mkm started coverage on Accuray in a research note on Tuesday, February 13th. They issued a “buy” rating and a $9.00 target price for the company. Finally, Roth Capital reaffirmed a “buy” rating on shares of Accuray in a research note on Tuesday, February 13th. One analyst has rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.25.

Accuray Trading Up 0.5 %

Shares of NASDAQ:ARAY traded up $0.01 during midday trading on Friday, reaching $2.19. 344,340 shares of the company’s stock were exchanged, compared to its average volume of 447,549. The firm’s 50 day simple moving average is $2.50 and its two-hundred day simple moving average is $2.65. The company has a debt-to-equity ratio of 3.53, a current ratio of 1.58 and a quick ratio of 0.84. The stock has a market cap of $217.18 million, a price-to-earnings ratio of -14.53 and a beta of 1.44. Accuray Incorporated has a fifty-two week low of $2.10 and a fifty-two week high of $4.30.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The business had revenue of $107.24 million for the quarter, compared to analyst estimates of $107.11 million. Accuray had a negative return on equity of 28.11% and a negative net margin of 3.25%. During the same period in the previous year, the business posted ($0.02) earnings per share. As a group, sell-side analysts forecast that Accuray Incorporated will post -0.07 EPS for the current fiscal year.

Accuray Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.